Article Text

Download PDFPDF
Viral entry inhibition: too late for hepatitis C, but promising for other viral infections

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Competing interests The author has received research grants from Gilead Sciences. He has served as an advisor for Abbvie, Achillion, Boehringer-Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Idenix, Janssen, Merck, Novartis, and Roche.

  • Provenance and peer review Commissioned; internally peer reviewed.

Linked Articles